Global
Vaccine Conjugates Market Overview
Conjugate vaccines are developed through a
covalent bond between a weak antigen and a strong antigen. This boosts the
immune response of the host towards various diseases. Conjugate vaccines are
germ specific and are capable of identifying just the targeted germs and
bacteria, making them usable as a preventive measure to provide additional
protection.
The global Vaccine
Conjugates Market Trends is anticipated to register a 15.2% CAGR
over the forecast period of 2022-2030. Various factors attributable to such
growth include a rising occurrence of diseases caused by various microorganisms
and bacteria. Further, a mounting awareness towards the prevention and
avoidance of infectious diseases is driving the global vaccine conjugates
market to a great extent. An increasing number of regulatory approvals to a
rising number of vaccines is expected to ascend the global vaccine conjugates
market by 2030.
However, complex manufacturing procedures
and low accessibility of vaccines to rural and remote areas are anticipated to
hinder growth in the global vaccine conjugates market. Moreover, recent
incidents of fraud and malpractice of top vaccine manufacturers are assessed to
refrain the market from augmenting during the forecast period. For instance, in
July 2018, a Chinese vaccine manufacturer was found guilty of fabricating its
manufacturing records and faced legal consequences.
Key
Players
The report by MRFR on global vaccine
conjugates market players are including
GlaxoSmithKline plc (U.K.),
Pfizer, Inc. (U.S.),
Merck & Co., Inc. (U.S.),
Sanofi Pasteur SA (France),
CSL Limited (Australia),
Emergent BioSolutions, Inc. (U.S.),
Johnson & Johnson (U.S.),
Medimmune, LLC (U.S.),
Astellas Pharma Inc. (Japan),
Serum Institute of India (India),
Bavarian Nordic (Denmark),
Mitsubishi Tanabe Pharma Corporation
(Japan),
Daiichi Sankyo Company,
Limited (Japan),
Fablife. (India),
SutroVax Inc. (U.S), and
Sinovac Biotech Ltd. (China).
Market
Segmentation
The global vaccine
conjugates market research is studied by Market Research Future (MRFR) for
various segments. This segmentation is carried out by type, disease indication,
patient stage, pathogen type, end-user, and region.
·
Based on type, the vaccine conjugates market is segmented into multivalent
conjugate vaccines and monovalent conjugate vaccines.
·
On the basis of disease
indication, the vaccine conjugates market is
segmented into influenza, DTP, pneumococcal, and meningococcal.
·
Based on pathogen type, the vaccine conjugates market is segmented into bacterial conjugate
vaccine, viral conjugate vaccine, and combination conjugate vaccine.
·
Based on patient stage, the vaccine conjugates market is segmented into adults conjugate
vaccine and pediatrics conjugate vaccine.
·
Based on end-user, the vaccine conjugates market has been segmented into academic
institutes, research institutes, and pharmaceutical industries.
Detailed
Regional Analysis
The global vaccine conjugates market
insights is segmented into the regions of the Americas, Europe, Asia Pacific,
and the Middle East and Africa. Among these regions, the Americas are expected
to spearhead the global vaccine conjugates market during the forecast period.
This market command can be accredited to the rising prevalence of infectious
diseases and increasing awareness of vaccination. Further, technological
advancements and rising government initiatives towards the encouragement of
vaccination programs are contributing to the heavy ascension of the vaccine
conjugates market. The Centers for Disease Control (CDC) has mentioned that
vaccination has proven as the best medium towards the prevention of diseases
and has reduced the impact of various life-threatening diseases.
On the other hand, Europe’s vaccine
conjugates market is highly driven by extensive research and development
activities in the fields of biotechnology and vaccine conjugates within various
countries in the region. The vaccine conjugates market in the region is
expected to register faster growth and is anticipated to follow the Americas.
Owing to the rising demand for genetically modified organisms, the market in
Europe is showcasing huge growth potential during the forecast period.
Asia Pacific is anticipated to grow at a
steady rate for vaccine conjugates during the forecast period. This can be owed
to a growing prevalence of geriatric population and the prevalence of
infectious diseases. Countries such as Singapore, India, China, and Japan are
projected to showcase extraordinary growth opportunities for vaccine conjugate
providers during the forthcoming years. Medical institutes in Asia Pacific are
primarily focusing on the use of vaccine conjugates and numerous research and
development activities over for the same.
About US:
Market Research Future (MRFR) enable
customers to unravel the complexity of various industries through Cooked
Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research
Reports (3R), Continuous-Feed Research (CFR), and Market Research &
Consulting Services.
Contact us:
Market Research Future (part of Wantstats
Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
